Wiśniewska Hanna, Skowron Miłosz, Bander Dorota, Hornung Monika, Jurczyk Krzysztof, Karpińska Ewa, Laurans Łukasz, Socha Łukasz, Czajkowski Zenon, Wawrzynowicz-Syczewska Marta
Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland.
Department of Anaesthesiology and Intensive Care, Marie Curie Hospital, Szczecin, Poland.
Am J Case Rep. 2020 Sep 25;21:e927452. doi: 10.12659/AJCR.927452.
BACKGROUND COVID-19 is an infectious disease caused by SARS-CoV-2. It has spread rapidly through the world, endangering human life. The main target of COVID-19 is the lungs; however, it can involve other organs, including the liver. Patients with severe COVID-19 have an increased incidence of abnormal liver function, and patients with liver disorders are considered to be at a higher risk of severe COVID-19 infection. The mechanism of liver injury reported in 14% to 53% of COVID-19 patients is poorly recognized and several possibilities need to be considered (cytokine storm, direct viral action, hypoxia). The incidence of underlying liver comorbidities in patients with a COVID-19 infection ranges from 1% to 11%. CASE REPORT This is a report of 2 nosocomial COVID-19 infections and severe COVID-19 pneumonia in 2 patients who were hospitalized during treatment for alcoholic liver disease (ALD). Case 1 and case 2 were a 31-year-old woman and a 40-year-old woman, respectively, with decompensated ALD and symptoms of the COVID-19 infection. Both patients were transferred from another hospital to our hospital after confirmation of COVID-19 during their hospitalization. The course of the infection progressed rapidly in both patients with the development of multiple-organ failure and death over a short period. CONCLUSIONS There are no clear recommendations on the management of ALD in the COVID-19 pandemic. Alcoholic hepatitis may be a risk factor for severe COVID-19 and a poor outcome. A high percentage of nosocomial COVID-19 infections are observed; therefore, special precautions should be taken to minimize the risk of COVID-19 exposure.
新型冠状病毒肺炎(COVID-19)是由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起的一种传染病。它已在全球迅速传播,危及人类生命。COVID-19的主要靶器官是肺;然而,它可累及其他器官,包括肝脏。重症COVID-19患者肝功能异常的发生率增加,而肝脏疾病患者被认为发生重症COVID-19感染的风险更高。在14%至53%的COVID-19患者中报告的肝损伤机制尚不清楚,需要考虑多种可能性(细胞因子风暴、病毒直接作用、缺氧)。COVID-19感染患者中潜在肝脏合并症的发生率为1%至11%。病例报告:本文报告2例酒精性肝病(ALD)患者在治疗期间住院发生的2例医院获得性COVID-19感染及重症COVID-19肺炎。病例1和病例2分别为一名31岁女性和一名40岁女性,均为失代偿期ALD且有COVID-19感染症状。两名患者在住院期间确诊COVID-19后均从另一家医院转入我院。两名患者的感染过程进展迅速,短期内出现多器官功能衰竭并死亡。结论:在COVID-19大流行期间,对于ALD的管理尚无明确建议。酒精性肝炎可能是重症COVID-19及不良预后的一个危险因素。观察到医院获得性COVID-19感染的比例较高;因此,应采取特殊预防措施以尽量降低COVID-19暴露风险。